Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Meta Plans to Call New Virtual Reality Headset the ‘Quest Pro’

News
Tech

Meta Plans to Call New Virtual Reality Headset the ‘Quest Pro’

-Bloomberg https://www.bloomberg.com/news/articles/2022-07-06/meta-plans-to-call-new-virtual-reality-headset-the-quest-pro

byCharles Gross

July 7, 2022

1 minute read

-Bloomberg

https://www.bloomberg.com/news/articles/2022-07-06/meta-plans-to-call-new-virtual-reality-headset-the-quest-pro

Legal
News

Minerva Neuroscience Granted Australian Patent Titled ‘Use of phenoxypropylamine compounds to treat depression’

By Benzinga Newsdesk

November 4, 11:05 AM

http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2020205268#

NERV

CBD Life Sciences Developing Bladder Control Supplement

By Vuk Zdinjak

September 21, 10:17 AM

LBC Bioscience Inc., a wholly owned subsidiary of CBD Life Sciences, (OTCPK:CBDL) is working towards launching a bladder control supplement.

CBDL

Moog Inc. Announces 4% Increased Cash Dividend To $0.27/Share

By Happy Mohamed

February 3, 9:09 AM

The Board of Directors of Moog Inc. (NYSE:MOG), a worldwide designer, manufacturer and systems integrator of high-performance precision motion and fluid controls and controls systems, declared a quarterly dividend

MOG

Goldman Sachs Maintains Sell on Helmerich & Payne, Lowers Price Target to $38

By Benzinga Newsdesk

July 13, 9:31 AM

Goldman Sachs analyst Neil Mehta maintains Helmerich & Payne (NYSE:HP) with a Sell and lowers the price target from $45 to $38.

Meta Plans to Call New Virtual Reality Headset the ‘Quest Pro’

Related Posts

Minerva Neuroscience Granted Australian Patent Titled ‘Use of phenoxypropylamine compounds to treat depression’

CBD Life Sciences Developing Bladder Control Supplement

Moog Inc. Announces 4% Increased Cash Dividend To $0.27/Share

Goldman Sachs Maintains Sell on Helmerich & Payne, Lowers Price Target to $38